Chapter title |
Epigenetics in Personalized Management of Lung Cancer.
|
---|---|
Chapter number | 6 |
Book title |
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
|
Published in |
Advances in experimental medicine and biology, December 2015
|
DOI | 10.1007/978-3-319-24932-2_6 |
Pubmed ID | |
Book ISBNs |
978-3-31-924931-5, 978-3-31-924932-2
|
Authors |
Ahmad, Aamir, Aamir Ahmad |
Editors |
Aamir Ahmad, Shirish M. Gadgeel |
Abstract |
In last several years, the focus on the origin and progression of human cancers has shifted from genetic to epigenetic regulation, with particular attention to methylation and acetylation events that have profound effect on the eventual expression of oncogenes and the suppression of tumor suppressors. A few drugs targeting these epigenetic changes have already been approved for treatment, albeit not for lung cancer. With the recent advances in the push towards personalized therapy, questions have been asked about the possible targeting of epigenetic events for personalized lung cancer therapy. Some progress has been made but a lot needs to be done. In this chapter, a succinct review of these topics is provided. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 60% |
France | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Scientists | 2 | 40% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 13 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 3 | 23% |
Student > Postgraduate | 2 | 15% |
Student > Ph. D. Student | 1 | 8% |
Other | 1 | 8% |
Professor > Associate Professor | 1 | 8% |
Other | 1 | 8% |
Unknown | 4 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 38% |
Biochemistry, Genetics and Molecular Biology | 3 | 23% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
Unknown | 4 | 31% |